Beta Bionics Celebrates Milestone: 10,000th iLet Patient
Beta Bionics, a commercial-stage medical technology company, proudly announces the 10,000th patient start on the iLet Bionic Pancreas. This significant milestone marks a major step forward...
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a bi-hormonal pump and pump systems. Xeris Biopharma...
Beta Bionics Announces the Nationwide Launch of the iLet Bionic Pancreas With Dexcom G7 CGM System
Beginning Dec. 18, iLet users will have the option of using a Dexcom G7 CGM System. Beta Bionics, Inc., a pioneering leader in the development...
Beta Bionics Announces iLet Bionic Pancreas Is Now Added to the Express Scripts National Commercial Formularies
Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced that effective November 10th, Express Scripts has added the iLet...
Beta Bionics Announces FDA Clearance and Commercialization of the iLet Bionic Pancreas
- First and only, automated insulin-delivery system that determines 100% of all insulin doses. - No carb counting*, no corrections, no calculating boluses. - Only...
Beta Bionics Appoints Dr. Steven Russell as Chief Medical Officer in Preparation for the Commercial Launch of the iLet Bionic Pancreas System
Caution: The iLet Bionic Pancreas is an investigational device limited by Federal law to investigational use. Not available for sale. Beta Bionics, Inc. — a clinical-stage...